SITE_DESCRIPTION
Investment Type: Venture Capital
Investment Stage: Series B
Portfolio 20
| Date | Name | Website | Total Raised | Location |
| 15.02.2026 | Breakthru ... | breakthrumed.com | - | - |
| 28.08.2025 | Incyclix B... | incyclixbio.com | $41.25M | United Sta... |
| 10.07.2025 | Paradigm T... | paradigmtherapeutics.com | - | - |
| 30.12.2024 | KOMO BIOSC... | komobiosciences.com | - | - |
| 30.12.2024 | MAI Founda... | medaditus.org | - | - |
| 30.12.2024 | Cavalry Bi... | cavalry.bio | - | United Sta... |
| 30.12.2024 | Genesis Bi... | genesisbiocapital.com | - | - |
| 09.02.2024 | Phoenix Mo... | phoenixmd.ca | $2.7M | United Sta... |
| 09.02.2024 | Jupiter | jupiter.bio | - | - |
| 04.01.2022 | Aravive (N... | aravive.com | $10M | - |
Show more
Mentions in press and media 9
| Date | Title | Description |
| 30.01.2026 | Breakthru Medicine: $60 Million Series A Raised For Building New Cancer Drugs | Breakthru Medicine has emerged from stealth after closing a $60 million Series A financing round, following a previously undisclosed seed round, and is developing new therapeutic modalities for cancer patients facing significant unmet needs... |
| 28.08.2025 | Incyclix Bio: $11.25 Million Series B Extension Secured For Treating Resistant Cancer | Incyclix Bio is a company working on advanced cancer treatments. They are developing a new drug called INX-315, a potent and selective inhibitor targeting CDK2, a protein that regulates the cell cycle. This drug aims to treat severe and res... |
| 21.06.2025 | Paradigm Therapeutics: A Beacon of Hope for Epidermolysis Bullosa Patients | In the world of biopharmaceuticals, every investment can be a lifeline. Paradigm Therapeutics, based in Mount Pleasant, South Carolina, recently secured an additional $12.6 million from Eshelman Ventures. This funding brings the total inves... |
| 18.06.2025 | Paradigm Therapeutics, Inc. Announces an Additional Investment by Eshelman Ventures, LLC to Expedite Global Development and Global Registration of SD-101, A Topical Therapy for Treatment Across the En... | First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used to Accelerate Activities Associated with Increasing Manufacturing Development of SD-101 and Commercial Laun... |
| 06.05.2025 | Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of... | First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with P... |
| 04.01.2022 | Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors | HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company’s Chairman, Fred Eshelman, Pharm.D... |
| 04.01.2022 | Aravive : Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors - Form 8-K | Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors Houston, TX, January 3, 2022 - Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage ... |
| 03.01.2022 | Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors | HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company’s Chairman, Fred Eshelman, Pharm.D... |
| 27.11.2020 | A donor who gave $2.5 million to a pro-Trump group looking for election fraud wants his money back after disappointing results | President Donald Trump at the White House on Thursday. Erin Schaff – Pool/Getty Images A venture capitalist who gave $US2.5 million to a pro-Trump group that said it was trying to find evidence of election fraud is now looking for a refund.... |